CA3161376A1 - Methods for improving neurological diseases and disorders - Google Patents

Methods for improving neurological diseases and disorders Download PDF

Info

Publication number
CA3161376A1
CA3161376A1 CA3161376A CA3161376A CA3161376A1 CA 3161376 A1 CA3161376 A1 CA 3161376A1 CA 3161376 A CA3161376 A CA 3161376A CA 3161376 A CA3161376 A CA 3161376A CA 3161376 A1 CA3161376 A1 CA 3161376A1
Authority
CA
Canada
Prior art keywords
patient
pabra
blocker
less
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3161376A
Other languages
English (en)
French (fr)
Inventor
Anthony P. FORD
Gabriel VARGAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curasen Therapeutics Inc
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of CA3161376A1 publication Critical patent/CA3161376A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3161376A 2019-12-18 2020-12-17 Methods for improving neurological diseases and disorders Pending CA3161376A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962950077P 2019-12-18 2019-12-18
US62/950,077 2019-12-18
US202063034364P 2020-06-03 2020-06-03
US63/034,364 2020-06-03
PCT/US2020/065655 WO2021127210A1 (en) 2019-12-18 2020-12-17 Methods for improving neurological diseases and disorders

Publications (1)

Publication Number Publication Date
CA3161376A1 true CA3161376A1 (en) 2021-06-24

Family

ID=76437605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3161376A Pending CA3161376A1 (en) 2019-12-18 2020-12-17 Methods for improving neurological diseases and disorders

Country Status (6)

Country Link
US (3) US11607395B2 (enExample)
EP (1) EP4076422A4 (enExample)
JP (1) JP7744344B2 (enExample)
AU (1) AU2020405091B2 (enExample)
CA (1) CA3161376A1 (enExample)
WO (1) WO2021127210A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法
US12616667B2 (en) * 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
CN115212194B (zh) * 2022-01-07 2024-08-13 中南大学湘雅三医院 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
CN116212002A (zh) * 2022-01-14 2023-06-06 中南大学湘雅三医院 一种预防或治疗缺血/再灌注损伤的药物组合物及应用
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
WO2023225021A1 (en) * 2022-05-17 2023-11-23 Curasen Therapeutics, Inc. Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US20260207533A1 (en) * 2022-12-21 2026-07-23 Curasen Therapeutics, Inc. Methods for treating various conditions and indications with agonists and antagonists
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025188807A1 (en) * 2024-03-06 2025-09-12 Curasen Therapeutics, Inc. Combination compositions and methods of use
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541188A (en) * 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
US7135497B1 (en) 2000-07-07 2006-11-14 New York Medical College Treating neural conditions resulting from spinal cord contusions and other causes
AU2003251949A1 (en) 2002-07-18 2004-02-09 Vanderbilt University Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype
CA2544611A1 (en) 2003-10-09 2005-04-21 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
US9492114B2 (en) 2004-06-18 2016-11-15 Banner Health Systems, Inc. Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease
US7528175B2 (en) 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
EP1754474A1 (en) 2005-02-02 2007-02-21 Eucro European Contract Research GmbH & Co. KG Use of S-Clenbuterol
US20080033027A1 (en) 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
WO2006108424A2 (en) 2005-04-13 2006-10-19 Astion Pharma A/S Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
US20070021421A1 (en) 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
CA2732513C (en) 2008-08-01 2017-04-25 Arca Biopharma, Inc. Methods and compositions involving (s)-bucindolol
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011133226A2 (en) * 2010-04-22 2011-10-27 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
EP2696849A4 (en) 2011-04-13 2014-10-29 Revalesio Corp COMPOSITIONS AND METHODS FOR INHIBITING AND / OR MODULATING EFFECTOR CELLS IN INFLAMMABLE NEURODEGENERATIVE ILLNESSES
US9784001B1 (en) 2011-05-03 2017-10-10 Paul Kristen, Inc Adjustable scaffolding suspension assembly
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
US20140256822A1 (en) 2013-03-11 2014-09-11 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
AU2014287418A1 (en) 2013-07-08 2016-01-28 Auspex Pharmaceuticals, Inc. Dihydroxyphenyl neurotransmitter compounds, compositions and methods
WO2015126915A2 (en) 2014-02-18 2015-08-27 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and social behavior in humans having deficits therein due to neurological disorders and compounds and compositions therefor
ES2864079T3 (es) * 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
US9889087B2 (en) 2014-06-10 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor
US10195198B2 (en) * 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
TWI728953B (zh) * 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
EP3398614B1 (en) 2015-12-29 2021-07-28 Kyoto University Agent for preventing and/or treating alzheimer's disease
BR112018073227A2 (pt) 2016-05-13 2019-02-19 The Board Of Trustees Of The Leland Stanford Junior University compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
WO2018195473A1 (en) 2017-04-20 2018-10-25 The Brigham And Women's Hospital, Inc. Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
US20220401415A1 (en) 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP7734700B2 (ja) 2020-06-04 2025-09-05 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物
WO2023225021A1 (en) * 2022-05-17 2023-11-23 Curasen Therapeutics, Inc. Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)

Also Published As

Publication number Publication date
EP4076422A4 (en) 2024-01-24
JP7744344B2 (ja) 2025-09-25
AU2020405091A1 (en) 2022-07-14
US11607395B2 (en) 2023-03-21
US20260151356A1 (en) 2026-06-04
US20230181492A1 (en) 2023-06-15
US20210186897A1 (en) 2021-06-24
EP4076422A1 (en) 2022-10-26
WO2021127210A1 (en) 2021-06-24
AU2020405091B2 (en) 2026-04-23
US12558325B2 (en) 2026-02-24
JP2023507408A (ja) 2023-02-22

Similar Documents

Publication Publication Date Title
US12558325B2 (en) Methods for improving neurological diseases and disorders
CA3100697A1 (en) Methods for diagnosing, monitoring and treating neurological diseases and disorders
CA3100848A1 (en) Methods for improving neurological diseases and disorders
US7408079B2 (en) Imaging agents and methods of imaging NAALADase or PSMA
US20230263749A1 (en) Compositions and methods for improving neurological diseases and disorders
JP4943159B2 (ja) 新規示差画像形成法
US20250134835A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US12616667B2 (en) Compositions and methods for improving neurological diseases and disorders
US20210251923A1 (en) Methods for improving neurological diseases and disorders
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists
WO2025188807A1 (en) Combination compositions and methods of use
US7081238B2 (en) Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
WO2024137506A1 (en) Compositions and methods for improving neurological diseases and disorders
Chen et al. A receptor-binding radiopharmaceutical for imaging of traumatic brain injury in a rodent model:[99mTc] Tc-tilmanocept
US20230357154A1 (en) Butyrylcholinesterase compounds and use in diseases of the nervous system
WO2023250332A1 (en) Compositions and methods involving isolated compounds
Halik et al. IN VIVO PHARMACODYNAMICS STUDIES OF NOVEL TACRINE DERIVATIVES RADIOCONJUGATES LABELLED WITH 68Ga AND 99mTc
Robert et al. Use of SPECT in early diagnosis and to monitor the effect of drugs in Alzheimer disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220822

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240820

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241017

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250215

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251003

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260108

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260126

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260126